CSIMarket
 
Advanced Container Technologies Inc   (ACOL)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 52
 Employees 22
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Advanced Container Technologies Inc

Through D&C Distributors LLC, we are in the business of selling proprietary plastic medical grade containers under the registered trademark “Medtainer®" that can store pharmaceuticals, herbs, teas and other solids or liquids, some of which can grind solids and shred herbs. We have received child safety certification for our 20-dram container and we are focusing our marketing efforts on drug stores and drug store chains, veterinarians and veterinary distributors and other distributors and end users. Through D&C Printing LLC, we are in the business of private labeling and branding for purchasers of containers and other products.

Through D&C Distributors LLC and and D&C Printing LLC, we are in the business of selling and distributing patented containers that can store, grind and shred pharmaceuticals, herbs, teas and other solids or liquids that are described under the caption “Description of Business – Products – The Medtainer®.” We provide custom printing of labeling for our products and products manufactured by others, as described under the caption, “Description of Business – Printing.”

We market directly to businesses through our phone room to the retail public through internet sales and, and to wholesalers and other businesses who resell our products to other businesses and end users.

Some of our products can be utilized for marijuana-related purposes. In light of the facts that the possession and use of marijuana have been legalized, subject to varying restrictions, in many states and that several other states are considering such legalization, we believe that our products may be of interest to a large number of users of marijuana in and we advertise our products on our website and elsewhere as suitable for that purpose. However, since we do not seek information from our customers who are end users as to how they intend to utilize our products and have no similar knowledge respecting end users of products sold through our distributor, we are unable to determine the extent of its use in connection with the storage and grinding of marijuana or any other purpose. We believe that marketing these products subjects us to the following risks.

The use of marijuana for medical and recreational use is lawful in many states, but under United States federal law and the laws of the other states, the possession, use, cultivation, storage, processing and/or transfer of marijuana is illegal. Federal and state law enforcement authorities have prosecuted persons engaged in these activities. While we do not believe that we engage in any of these activities, any of these law enforcement authorities might bring an action against us in connection with the engagement of others in them, including, but not limited, to a claim of aiding and abetting their criminal activities. Such an action would have a material and adverse effect on our business and operations.


· Under United States federal law, it is unlawful to sell or offer for sale, to use the mails or any other facility of interstate commerce to transport or to import or export drug paraphernalia. The term “drug paraphernalia” includes any equipment, product or material of any kind which is primarily intended or designed for use in manufacturing, compounding, converting, concealing, producing, processing, preparing, injecting, ingesting, inhaling, or otherwise introducing into the human body a controlled substance. One of the factors that these authorities may consider in determining whether our products are drug paraphernalia are our national and local advertising concerning its use and we have advertised our products as usable for marijuana-related purposes. However, we do not believe that our products were designed or are intended for any of these purposes or that our products are drug paraphernalia, as defined in federal law, and we are promoting our products primarily to be used for other purposes. If federal authorities were to take a different view, they might bring a criminal action against us. Such an action would have a material and adverse effect on our business and operations. During the administration of President Barack H. Obama, enforcement of such federal law was relaxed, but there have been indications that the administration of President Donald J. Trump may enforce it differently. We are presently unable to predict what effect, if any, this change, if it occurs, would have on us or our business.



   Company Address: 1620 Commerce St. Corona 92878 CA
   Company Phone Number: 381-2555   Stock Exchange / Ticker: ACOL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TUP   -1.32%    
• View Complete Report
   



Exagen Inc

Evanescence of Deficit: XGN Struggles with Weakness in Fourth Quarter Financial Report

Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior.
Although there was a 7.229% increase in revenue to $13.77 million from $12.84 million in the corresponding reporting season, this is a relatively small growth rate and not enough to inspire confidence in the company's prospects. The sequential revenue growth of 2.601% from $13.42 million is also modest at best.

Enzo Biochem Inc

Enzo Biochem Inc Revenue Plummeted during November to January 31, 2024 Period

Enzo Biochem Inc, a medical laboratories company, experienced a stable stock performance in March 2024 with no change in its share price. However, this brings the share price to a decrease of 11.33% in the first quarter of 2024. Additionally, the stock is currently trading only 33% above its 52-week low.
For the financial second quarter of 2024, Enzo Biochem Inc reported a significant improvement in its earnings per share (EPS) compared to the previous year. The loss per share decreased from $-0.23 to $-0.06. Furthermore, the EPS also improved from the preceding quarter, going from $-0.13 to $-0.06.

Ispecimen Inc

iSpecimen Inc. Faces Deficit on Weak Sales as Financial Period Ends December 31, 20232.

iSpecimen Inc. (Nasdaq: ISPC) is a pioneering online marketplace that connects scientists with healthcare specimen providers for research purposes. The company, headquartered in Lexington, Massachusetts, has recently announced that it will unveil its full-year financial results for the period ending December 31, 2023, on March 13, 2024. Stakeholders are eagerly awaiting the release of these results, as iSpecimen is globally recognized for its innovative platform that facilitates breakthrough discoveries and accelerates scientific advancements.
The previous fiscal span, from October to December 31, 2023, saw iSpecimen Inc. experience a deficit per share of $-0.33, compared to $-0.20 the previous year. This represents a growth in deficit per share from $-0.23 from the prior reporting season. Additionally, the company's revenue declined by -13.049% to $2.58 million from $2.96 million in the comparable reporting season a year before. Sequentially, revenue deteriorated by -7.296% from $2.78 million.

Maxcyte Inc

Maxcyte Inc. Sees Revenue Surge, But Fails to Reach Profitability Goals in Q4 2023

Maxcyte Inc, a leading cell-engineering focused company, recently announced its fourth quarter and full year financial results for 2023. The company reported a surge in revenue by 26.087% to $15.66 million from the same reporting period a year before. However, it also experienced diminishing returns with a net shortfall of $-0.05 per share.
Despite the positive revenue growth, Maxcyte Inc's shares have gone down by -15.63% in the past 5 trading days and -14.35% from a year ago. Currently, the company's shares are trading on the NASDAQ by -8.4% below its 52 week average.

Butterfly Network Inc

Butterfly Network Inc Surprises with Decreased Loss Per Share, Revenue Decline in Q4 2023

Butterfly Network Inc Reports Decreased Loss Per Share, Declining Revenue for Q4 2023
BURLINGTON, Mass. and NEW YORK - Butterfly Network, Inc. (NYSE: BFLY), a digital health company focused on portable, semiconductor-based ultrasound technology, announced its financial results for the quarter and year ended December 31, 2023. The company also provided an update on its business activities. Butterfly Network aims to make medical imaging more accessible through its innovative product offerings, software solutions, and educational programs.
For the financial period closing December 31, 2023, Butterfly Network reported a loss of $-0.21 per share, showing an improvement from the loss of $-0.31 per share in the previous year. However, there was an increased loss compared to the previous reporting period, from $-0.13 per share. The company's revenue declined by 14.346% to $17.08 million from $19.94 million, in the comparable reporting period a year prior. Nevertheless, sequentially, the revenue advanced by 11.013%, from $15.38 million.






 

Advanced Container Technologies Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com